X4 Pharmaceuticals Valuation Multiples

X4 Pharmaceuticals Overview

About X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Founded

2010

HQ

Employees

143

Website

x4pharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $28M

Net Income: ($89M)

EV

$197M

Valuation Multiples

Multiples.vc

Start free trial

X4 Pharmaceuticals Financials

X4 Pharmaceuticals reported last 12-month revenue of $28M.

In the same LTM period, X4 Pharmaceuticals generated $23M in gross profit and had net loss of ($89M).

X4 Pharmaceuticals P&L

In the most recent fiscal year, X4 Pharmaceuticals reported revenue of $35M and EBITDA of ($69M).

X4 Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

X4 Pharmaceuticals Stock Performance

X4 Pharmaceuticals has current market cap of $373M, and enterprise value of $197M.

X4 Pharmaceuticals' stock price is $4.10.

X4 Pharmaceuticals Valuation Multiples

X4 Pharmaceuticals trades at 7.1x EV/Revenue multiple, and (2.9x) EV/EBITDA.

X4 Pharmaceuticals Financial Valuation Multiples

As of April 11, 2026, X4 Pharmaceuticals has market cap of $373M and EV of $197M.

Equity research analysts estimate X4 Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

X4 Pharmaceuticals has a P/E ratio of (4.2x).

X4 Pharmaceuticals Margins & Growth Rates

X4 Pharmaceuticals' revenue in the last 12 month declined by (72%).

X4 Pharmaceuticals' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.8M for the same period.

X4 Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

X4 Pharmaceuticals M&A Activity

X4 Pharmaceuticals acquired XXX companies to date.

Last acquisition by X4 Pharmaceuticals was on XXXXXXXX, XXXXX. X4 Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

X4 Pharmaceuticals Investment Activity

X4 Pharmaceuticals invested in XXX companies to date.

X4 Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. X4 Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).